PCPC: 'Double Fees' For Cosmetic-Drug Products Are Regulatory Reform Concern
This article was originally published in The Rose Sheet
Executive Summary
Cosmetic products containing OTC drug ingredients – such as acne-fighting agents and UV filters in skin-care and makeup items, fluoride in toothpaste and dandruff medication in shampoo – could be subject to multiple fees if FDA's concept for generating OTC monograph program funding were to become a reality along with the Personal Care Products Safety Act.
You may also be interested in...
All Roads For OTC Policy Improvements Lead To User Fees, FDA Suggests
In an update on discussions with industry about potential user fees to support FDA's OTC monograph program, CDER officials say "industry and public would suffer" absent new fees.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.